Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

April 29, 2024

https://www.globenewswire.com/news-release/2024/04/29/2871068/0/en/Atea-Announces-Presentation-of-Data-Highlighting-Favorable-Safety-Profile-of-Bemnifosbuvir-at-ESCMID-Global-2024.html

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of Phase 1 data highlighting the safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor, at the European Society of Clinical Microbiology & Infectious Diseases Global 2024 (ESCMID, formerly ECCMID), which is taking place April 27-30, 2024 in Barcelona, Spain.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.